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Mycobacterium tuberculosis thymidine monophosphate kin-
ase (TMPKmt) has recently been introduced as a potential
target for the structure-based design of anti-tuberculosis
drugs. Based on the TMPKmt X-ray structure and previous
S.A.R. studies, we synthesised the nucleoside analogues
3a−b, 6a−b, 7a−b, and 8a−b, modified in 2- and 3-position
of the ribofuranose ring moiety. To our surprise, these ana-
logues showed only moderate binding affinity (i.e. Ki be-
tween 118 and 1260 µM). This prompted us to investigate the
conformational features of these nucleosides. We concluded
Introduction
Each year Mycobacterium tuberculosis, the intracellular
parasite that causes tuberculosis (TB), kills approximately
2 million people.[1] The World Health Organization (WHO)
declared TB a global health emergency and estimates that
between 2002 and 2020 approximately 1000 million people
will be newly infected and 36 million will die from TB.[2,3]
Major contributors to the resurgence of this pulmonary dis-
ease and its worsening impact are the breakdown in health
services, the pandemic of AIDS and the emergence of multi-
drug-resistant (MDR)-TB.[3] The immune system can ‘‘wall
off’’ the bacilli, allowing TB to stay dormant for years and
to emerge when the immune system is weakened. This ex-
plains why TB is a leading cause of death among HIV-posi-
tive persons.[3,4] The current treatment strategy of TB is
based on an intensive 6 to 8-month regimen of multiple
antibiotics such as rifampicine, isoniazid, pyrazinamide,
and ethambutol or streptomycin.[5] However, Mycobacter-
ium tuberculosis strains resistant to some or all of these
major anti-TB drugs have emerged and are associated with
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that compounds of this series, especially 8a−b, are strongly
biased towards the ‘‘Northern’’ furanose ring conformation,
whereas X-ray crystallography reveals a preference of
TMPKmt for the opposite ‘‘Southern’’ conformers. This paper
covers the synthesis, biological evaluation and conforma-
tional features (i.e. preferred ring puckering) of the 2- and
3-modified dT analogues.
( Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2003)
high death rates of 5080%.[6] The ‘‘MDR’’ prefix refers to
the simultaneous resistance to at least isoniazid and rifam-
picin, the two most potent anti-TB drugs, caused primarily
by inconsistent, partial or improper treatment regimens.
These facts impose the need to identify new targets and
to develop new anti-TB drugs in order to optimise and/or
shorten the current TB treatment and to combat resistance.
In that light, Mycobacterium tuberculosis thymidine mono-
phosphate kinase (TMPKmt), an essential enzyme of nucle-
otide metabolism that catalyses the reversible phosphoryl-
ation of thymidine monophosphate (dTMP) to thymidine
diphospate (dTDP), has recently been introduced as a novel
potential target for chemotherapeutic intervention.[7,8] Al-
though the global fold of the TMPKmt enzyme is similar
to that of other TMPK isozymes, it has a low degree of
amino acid sequence identity with the E. coli (26 %), yeast
(25 %) and human (22 %) isozymes, making it an attractive
target for blocking mycobacterial DNA synthesis.[8] The X-
ray structure of the dTMP-TMPKmt complex indicated
that the main binding interactions between dTMP and the
enzyme involve both its pyrimidine base (i.e. stacking inter-
action with Phe70 and O4 and N3 participating in hydrogen
bonding with Arg74 and Asn100) and its ribofuranose ring
moiety (i.e. hydrogen bond between the 3-hydroxyl of
dTMP and the terminal carboxyl of Asp9).[8] The presence
of a tyrosine residue (Tyr103) close to the 2-position allows
the enzyme to discriminate between 2-deoxynucleotides
and ribonucleotides, only transforming the former.[8] Also
this X-ray analysis revealed the substrate to adopt the
‘‘Southern’’ conformation.[8]
S. Van Calenbergh et al.FULL PAPER
The fact that thymidine (dT) and 3-azido-3-deoxythym-
idine (AZT) proved to be competitive inhibitors of
TMPKmt with low µ affinity,[9] led towards the synthesis
and biological evaluation of several dT nucleoside and nu-
cleotide analogues.[911] In this paper we continue our se-
arch for nucleosidic TMPKmt inhibitors by combining
favourable modifications at C-3 (N3, NH2) with the ben-
eficial effects observed upon introduction of an α-chloro or
α-fluoro substituent at C-2.[10,11] Using NMR spectroscopy
and pseudorotational analysis, we examined the solution
state conformation of the sugar ring of the synthesised ana-
logues to gain better insight into the molecular determi-
nants of TMPKmt inhibition.
Results and Discussion
Chemical Synthesis of 2 and 3 Modified dT Analogues
The commercially available 1,2-O-isopropylidene-α--xy-
lofuranose (1, Scheme 1) was converted to 3-azido-ribofur-
anose 2 according to a literature procedure.[12]
Vorbrüggen[13] type coupling of 2 with silylated thymine,
followed by alkaline deprotection afforded the azido nu-
Scheme 1. Synthesis of 2- and 3-modified thymidine nucleoside analogues: (a) (i) thymine, [(CH3)3Si]2NH, (CH3)3SiCl, CF3SO2OSiMe3,
pyridine, 1,2-dichloroethane, room temp., (ii) 0.15  NaOCH3 in MeOH, room temp., (iii) adjusted to pH  7 with H2O/AcOH (9:1);
(b) (i) triphenylmethyl chloride, pyridine, 65 °C, 48 h, (ii) CF3SO2Cl, DMAP, CH2Cl2, 4 °C; (c) (i) 1  NaOH, EtOH/H2O (1:1), room
temp., (ii) adjusted to pH  7 with HOAc; (d) 80 % CH3COOH, 90 °C; (e) 4  HCl in 1,4-dioxane; (f) (i) DAST, pyridine, tolueen, 50
°C, (ii) 80 % CH3COOH, 90 °C; (g) Ph3P, NH4OH, pyridine, room temp.
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cleoside 3a[14]. After tritylation of the primary hydroxyl
group, 3a[14] was converted into the 2,2-anhydro-analogue
4.[15] Alkaline treatment of 4 yielded intermediate 5 with the
2-hydroxyl group in the arabino (‘‘UP’’) configuration.[16]
Detritylation of 5 with 80 % HOAc quantitatively yielded
nucleoside 6a[17]. Nucleophilic chlorination of 4 with 4 
HCl in dioxane[18] resulted in the formation of 1-(3-azido-
2-chloro-2,3-dideoxy-5-O-trityl-β--ribofuranosyl)-
thymine (7a). Analogue 5 was treated with DAST[19] and,
after detritylation, nicely afforded nucleoside 8a with the
fluorine atom at the 2-position of the sugar moiety in ribo
(‘‘DOWN’’) configuration. This approach towards the syn-
thesis of 8a improved the methods previously described.[20]
Selective triphenylphosphane reduction of the azido moiet-
ies of nucleosides 3a[14], 6a[17], 7a and 8a[20] smoothly af-
forded the novel 3-amine functionalised analogues 7b and
8b and the known 3b[21a] and 6b[21b].
TMPKmt Affinity (Inhibition Studies)
Results of the binding studies are presented in Table 1.
The 3-azido and 3-amino substituents are intended for di-
rect interaction with Asp 9. With the 2-modifications we
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explored if an α-chloro or α-fluoro substituent in the vicin-
ity of Tyr103 would be sterically tolerated.
Table 1. Kinetic parameters of Mycobacterium tuberculosis thymid-
ylate kinase with the 2- and 3-modified thymidine analogues
Analogue R1 R2 R3 Ki [µ]
dT[9] OH H H 27
AZT[9] N3 H H 28
3a N3 OH H 740
3b NH2 OH H 750
6a N3 H OH 215
6b NH2 H OH 1260
7a N3 Cl H 170
7b NH2 Cl H 145
8a N3 F H 118
8b NH2 F H 190
As expected, the introduction of the 2-hydroxyl function
in 3a and 3b had adverse effects on the affinity, due to an
unfavourable interaction with the nearby tyrosine residue
(Tyr103). Indeed, the affinity markedly improves when the
2-hydroxyl adopts the opposite arabino configuration in 6a
(Ki  215 µ), or when the 2-ribo-hydroxyl (in 3ab) is
replaced by a chloro or fluoro atom in 7ab and 8ab,
respectively. The incorporation of a fluoro atom into the
sugar moiety of nucleosides has great impact on the biologi-
cal and chemical characteristics of these molecules.[22] The
strong electronegative fluorine alters the electronic proper-
ties of the molecule and specifically tunes the conformation
of the furanose ring.[22b][22c] Also, the 2-α-fluoro atom in
8ab isosterically replaces a hydrogen atom and is known
to greatly enhance the stability of the glycosidic bond.[18]
Still, the affinity for 7ab and 8ab is moderate, i.e.  100
µ. This was not expected, since earlier work suggested ‘‘to
combine a 2-chlorine and 3-azido group’’.[10] Further-
more, the 3-amino analogues 7b and 8b, showed no en-
hanced TMPKmt affinity compared to their 3-azido forms
7a and 8a, indicating that the positively charged 3-amine
is not optimally oriented to form an ionic interaction with
Asp9. These results prompted us to investigate the preferred
puckering of the furanose ring of the 2- and 3-modified
7ab and 8ab pairs.
NMR Spectroscopy
NMR spectroscopy in D2O permits extension of the re-
sults to the in vivo/ in vitro situation and was used for the
pseudorotational analysis[23] of nucleosides 7ab and
8ab. The complete conformational analysis of a nucleo-
side (or nucleotide) usually comprises the determination of
three principal structural parameters: (1) the glycosidic tor-
sion angle χ, which determines the syn or anti position of
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the base relative to the sugar moiety; (2) the torsion angle
γ, which determines the orientation of the 5-hydroxyl with
respect to the C3; and (3) the puckering of the furanose
ring and its deviation of planarity, described by the phase
angle of pseudorotation P (0360°) and the maximum out-
of-plane pucker νmax (3046°).[23] Here, we only focussed
on the latter, since (a) the ring puckering is known to be
the main determinant in controlling the γ- and χ-angles;[24]
(b) most probably a strong preference for a specific C4-C5
rotamer (γ-angle) is induced by the enzyme upon binding;
and (c) as evidenced by the crystal structure data,[8]
TMPKmt binds its substrates with the base in the anti posi-
tion (χ-angle).
In solution, the relative strengths and interplay of im-
portant anomeric and gauche effects[24,25] drive the prefer-
ence of the flexible furanose ring moiety of N-nucleosides
between the north (N) and south (S) type puckered pseudo-
rotamers. By convention, a phase angle P  0° corresponds
to the absolute N conformation possessing a symmetrical
twist form 3T2 (C3-endo-C2-exo), whereas the S antipode
twist, 2T3 (C2-endo-C3-exo), is represented by P 
180°.[23] Along the pseudorotational cycle, the confor-
mation of the furanose ring alternates between envelope (E)
and twist (T) conformations every 18°. We measured vicinal
proton-proton coupling constants (3J1,2, 3J2,3, and 3J3,4)
of 7ab and 8ab at 500 MHz in D2O (ca. 40 mM) in a
278333 K range at pD 7.4 (see Table 2).
Table 2. 3JH,H coupling constants [Hz] and population of S con-
formers at five distinct temperatures in the range from 278 to 333 K
Temp. [K] 3J1,2[a] 3J2,3 3J3,4 XS [%][b]
7a
278 4.70 5.55 6.21 45
288 4.76 5.59 6.25 45
300 4.92 5.61 6.39 46
318 5.06 5.63 6.43 47
333 5.20 5.67 6.49 48
7b
278 2.12 4.93 8.17 16
288 2.30 4.94 8.11 17
300 2.50 4.94 7.91 20
318 2.66 4.95 7.80 21
333 2.69 4.95 7.73 22
8a
278 1.27 4.73 9.31 3
288 1.54 4.78 9.24 5
300 1.66 4.81 9.19 7
318 1.69 4.88 9.07 8
333 1.72 4.89 9.05 8
8b
278  1.00 4.30 9.70  1
288  1.00 4.49 9.92  1
300  1.00 4.79 9.97  1
318  1.00 4.81 10.01  1
333  1.00 4.82 10.07  1
[a] 3JH,H recorded at 500 MHz in D2O at pD 7.4. [b] The PSEUROT
program (version 6.2)[26] has been used to derive populations as
well as geometries of N and S coformers (see Table 3) at stated tem-
perature.
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Subsequently, we used the computer program PSEUROT
6.2[26] to calculate, at each temperature interval, the best fit
of five conformational parameters, i.e. P and νmax for both
N and S conformers and the mole fraction of S (XS), based
on the three experimental coupling constants (see Tables 2
and 3).
Table 3. Optimized pseudorotational parameters and errors of
pseudorotational analysis[a] based on 3JH,H measured at five dis-
tinct temperatures in the range of 278 to 333 K
Analogue PN νmax,N PS νmax,S rms
[deg] [deg] [deg] [deg] [Hz][b]
7a 2.7 37.5 132.7 38.8 0.110
7b 7.7 38.4 162.7 38.2 0.020
8a 28.7 34.6 146.1[c] 36.0[c] 0.042
8b 31.2 36.5 151.8[c] 30.0[c] 0.172
[a] The least-squares minimization program PSEUROT (version
6.2)[26] has been used for 3JH,H and equilibrium populations of
NoS equilibrium at various temperatures see Table 2. [b] The rms
deviation represents the deviation of calculated and experimental
3JH,H: rms  {1/nΣ[Jiexpt  Jitheor (PN, ν˜max,N, PS, ν˜max,S)]2}1/2. [c]
The pseudorotational parameter was kept fixed during optimis-
ation.
The preferred solution state conformation of 7a, 7b, 8a,
and 8b is determined by a variety of factors, but is primarily
influenced by the class and positioning of the 2- and 3-
substituents and the complex interplay of the resulting four
gauche interactions, i.e. O4C4C3R3,
O4C1C2-R2, R2C2C3R3, and
N1C1C2R2. The mole fraction of S at 30 °C (XS)
shows these analogues prefer the ‘‘northern’’ type ring
puckering (see Table 4). In combination with the 3-azide
modification, the 2-chloro derivative 7a (PN  2.7°,
νmax,N  37.5°) virtually adopts a 3T2 (C3-endo-C2-exo
twist) conformation, whereas the 2-fluoro analogue 8a
(PN  28.7°, νmax,N  34.6°) exhibits a conformation that
lies between a 3E (C3-endo envelope) and 3T4 (C3-endo-
C4-exo twist). For the 3-amino modified compounds, the
puckering of the 2-chloro derivative 7b (PN  7.7°,
νmax,N  38.4°), is in between a 3T2 (C3-endo-C2-exo
twist) and 3E (C3-endo envelope), whereas the 2-fluoro de-
rivative 8b (PN  31.2°, νmax,N  36.5°) is close to a 3T4
(C3-endo-C4-exo twist). Our results show that when 3-
azido/amino and 2-chloro/fluoro modifications are com-
bined, the pseudo-axial position of the 2-halogens and the
resulting O4C1C2R2 gauche effect are directing the
furanose ring towards the ‘‘northern’’ hemisphere of the
pseudorotational circle. This O4C1C2R2 gauche in-
teraction and its drive towards the N-type conformers is
cooperative with the anomeric effect[25] and, as evidenced
by the XS-values of 7ab ( 46 %) vs. 8ab ( 6 %) (see
Table 4), relates to the electronegativity of the 2-substitu-
ents. This is in line with previous findings.[22c,27] Marquez
et al.[22c] proved the pseudorotational equilibrium to be go-
verned by the α- or β-oriented fluorine atoms in 2- or 3-
position and their tendency to adopt a pseudo-axial orien-
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tation. Furthermore, the comparative solution confor-
mation analysis of both 3-α-fluorothymidine (FLT) and
AZT clearly demonstrated that the small, electronegative
3-fluorine atom was practically locked in the pseudo-axial
position (due to the strong O4C4C3F gauche inter-
action), whereas the sterically larger 3-azide showed no
clear positional preference.[22b] Here, however, without pro-
per energetic quantification of the various stereoelectronic
effects in 7ab and 8ab, we can only postulate that the
O4C1C2Cl/F gauche effect dominates the opposite
O4C4C3N3/NH2 gauche effect and decreases as size
increases and/or electronegativity decreases (cf. 7ab vs.
8ab). Only the S-type conformers of 7a and 7b are rel-
evant (for, 8a-b XS  6 %). The 2-chloro-3-azido modified
7a (PS  132.7°, νmax,N  36.5°) has a conformation in
between a 1E (C1-exo envelope) and 2T1 (C2-endo-C1-
exo twist), whereas the 3-amino derivative 7b (PS  162.7°,
νmax,N  36.5°) has a perfect 2E (C2-endo envelope) S-
type conformation.
X-ray crystallographic analysis of TMPKmt complexed
dTMP shows that the furanose ring of the substrate is bi-
ased towards the ‘‘south’’.[8,10] The preference of 7ab and
8ab for the opposite ‘‘northern’’ conformation results in
the pseudo-equatorial positioning of the 3-azide/amine and
can explain their moderate affinity for TMPKmt. The 3-
hydroxyl function of dTMP interacts directly with an as-
partate residue (Asp9) in the TMPKmt binding site.[8] The
positional shift of the 3-azido/amino substituents, when
puckered in N, might result in an ineffective contact with
this Asp9 and hence lower the affinity. The introduction of
a methylene spacer between the 3-azido/amino group and
the C3, the so-called ‘‘branched chain’’, might restore the
hampered interaction with Asp9 and consequently improve
the affinity.
NoS Energy Calculations
Generally, in the solid state, mainly influenced by crystal
packing forces,[28] only one of the two solution confor-
mations (N or S) is present.[24] Similarly, when a nucleoside
(or nucleotide) binds to its target only one form is expected
to be present. Although the NoS energy difference is about
4 kcal/mol for classic nucleosides and nucleotides,[24] it can
explain their differences in binding affinity.[29] We estimated
the enthalpy (∆H°) and the entropy (∆S°) of the NoS two-
state pseudorotational equilibrium for 7ab and 8ab
from the slopes and intercepts of the van’t Hoff plots [ln(XS/
XN) vs. 1/T] (see Table 4). The signs of the thermodynamic
parameters (∆H°, ∆S°, and ∆G°) are arbitrary chosen so
that positive values indicate the drive of NoS equilibrium
to N, as is the case for 7ab and 8ab, whereas negative
values would describe the drive towards S.
Note that at 30 °C the ∆H° and ∆S° contributions to the
∆G° of the pseudorotational equilibrium in 7ab and 8ab
are quite different and that it is the significant ∆H° contri-
bution that drives the pseudorotational equilibrium to the
‘‘north’’. Although the ∆G°-values for 7a and 7b are posi-
tive, their ∆H° contribution to ∆G° is rather low (1.8 kJ/
mol and 5.7 kJ/mol respectively) and indicates the NoS
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Table 4. Values for ∆H° and ∆S° of the NoS conformational equil-
ibria as obtained through van’t Hoff plots, ∆G°, and population of
the S conformer at 303 K
Analogue ∆H[a] ∆S[a] ∆G[b] XS[c] [%]
[kJ/mol] [J/mol K] [kJ/mol]
7a 1.8 4.6 0.38 46
7b 5.7 6.8 3.6 19
8a 13.7 22.4 7.0 6
8b 21.1 1.2 20.7  1
[a] ∆H° and ∆S° were calculated from the slope and intercept of
the line obtained through the least-squares fitting procedure of ln
(XS/XN) to the reciprocal of temperature: ln(XS/XN)  (∆H°/
R)·(1/T)  (∆S°/R). R is the gas constant (8.31 J/mol·K). [b] Calcu-
lated Gibbs free energy at 303 K (∆G°  ∆H°  T∆S°). [c] The
population of the S conformer at 303 K through the relation XS/
XN  K  exp(∆G303/RT).
equilibrium can be easily driven towards S by the enzyme
upon binding. More likely, their rather poor affinity, i.e.
Ki  150 µ (see Table 1), results from the steric clash be-
tween the larger 2-α-chloro atom with Tyr103. In case of
7ab however, this effect is not so dramatic as for the 2-
α-hydroxyl in 3ab, which probably relates to the greater
hydrophobicity of the chloro atom. The ∆H° contributions
of 8a and 8b (13.7 kJ/mol and 21.1 kJ/mol respectively), on
the other hand, suggest that the NoS equilibrium is
strongly biased towards N, the antipodal conformation of
the S puckering preferred by TMPKmt.[8] Such an energy
gap might not easily be overcome by TMPKmt and, to-
gether with the uneffective pseudo-equatorial position of
the 3-azide/amine, plausibly accounts for the moderate Ki
values of 8a and 8b. This conformational rigidity of 8a is
also a possible explanation for the lack of anti-HIV-1 ac-
tivity.[20b] The strong tendency of 8a to adopt a N-type
puckering probably hampers the activation of this nucleo-
side to its triphosphate counterpart by cellular kinases,
known to prefer S conformers as substrates.[30]
Conclusion
In search for new treatment strategies against tubercu-
losis, Mycobacterium tuberculosis thymidine monophos-
phate kinase (TMPKmt) was previously introduced as a po-
tential target for the rational design of inhibitors. Stimu-
lated by the fact that thymidine and 3-α-azido-thymidine
proved to be potent inhibitors, we further elaborated our
research towards the rational design of new leads based on
the TMPKmt crystal structure. This work describes the syn-
thesis and biological evaluation of a number of 2-and 3-
modified thymidine analogues (3ab, 6ab, 7ab, and
8ab).
As expected the combination of 3-azide/amine and 2-α/
β-hydroxyl substitutions, i.e. for 3ab and 6ab, decreased
the affinity significantly due to interaction with a tyrosine
residue (Tyr103) known to be in the vicinity of the 2-posi-
tion. To our surprise the combination of 3-azide/amine and
2-chloro/fluoro substituents (7ab and 8ab), known to
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be beneficial for the TMPKmt affinity when introduced
separately, only resulted in moderate binding properties.
This prompted us to investigate the conformational aspects
of these thymidine analogues. In solution the sugar ring of
nucleosides and nucleotides is known to exist in a rapid
dynamic equilibrium, between the extreme ‘‘northern’’ (N)
and the opposite ‘‘southern’’ (S) conformations. When a nu-
cleoside or a nucleotide binds to its target enzyme, like in
the crystal, only one of the two solution conformations is
expected to be present in the active site. Through the NMR
spectral parameters of 7ab and 8ab, i.e. vicinal coupling
constants (3JH,H), and their subsequent analysis with the
PSEUROT program we indicated these analogues to be bi-
ased strongly towards the N conformation of the furanose
ring. Via van’t Hoff plots we also calculated the energy
(∆H°, ∆S° and the resulting ∆G°) for the NoS equilibria
of 7ab and 8ab. Keeping the binding affinity of these
derivatives in mind, our conformational analysis and energy
calculations show to have important implications on: (i) the
appropriate positioning of the 2- and 3- substituents; (ii)
the ability of the enzyme to induce an S-type puckering on
its ligand.
The discrepancy between the conformation of the sub-
strate from the target X-ray structure and the solution state
conformation of the analogues examined, indicates the
danger of only using crystal structural data for the formu-
lation of structure-activity relationships. These findings will
allow us to further rationally design other 2- and 3-modi-
fied thymidine analogues, considering the influence of the
planned modification (in, 2- and 3-position) on both po-
tential binding interactions and conformational preference.
Experimental Section
General Remarks: 1H and 13C spectra were obtained with a Varian
300 MHz spectrometer (1H NMR: 300 MHz. 13C NMR: 75 MHz).
The residual solvent signal of [D6]DMSO was used as a secondary
reference. Assignment of all 1H-resonances was confirmed by 2D
1H-1H COSY experiments. The signals assigned to amino and hy-
droxyl groups were exchangeable with D2O. Abbreviations used are
s  singlet, d  doublet, t  triplet, q  quadruplet, m  mul-
tiplet, dd  double of doublets, app  apparent, and br  broad
signal. Coupling constants (J) are expressed in Hz. Exact mass
measurements were performed on a quadrupole/orthogonal-accel-
eration time-of-flight (Q/oaTOF) tandem mass spectrometer
(qTOF 2, Micromass, Manchester, UK) equipped with a standard
electrospray ionisation (ESI) interface. Samples were infused in a
2-propanol/water (1:1) mixture at 3 µL/min. Precoated
MachereyNagel & Co.,  SIL G/UV254 silica gel plates
were used for TLC and spots were examined with UV-light at
254 nm and/or a sulfuric acidanisaldehyde solution or a ninhyd-
rin (0.5% in EtOH) solution. Column chromatography was per-
formed on silica gel 560 (0.060.2 mm) from Uetikon Chemie. 1,2-
O-isopropylidene-α--xylofuranose (1), reagents, anhydrous Et2O,
pyridine and toluene were purchased from  .
CH2Cl2, ClCH2CH2Cl and MeOH were obtained by distillation
after refluxing overnight on CaH2.
1,2-Di-O-Acetyl-3-azido-5-O-(4-methylbenzoyl)-3-deoxy-β-D-ribo-
furanose (2): According to ref.[12b] Exact mass (ESI-MS, iPr-
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OH:H2O) calculated for C17H19N3O7Na [M  Na] 400.1120;
found 400.1198.
1-(3-Azido-3-deoxy-β-D-ribofuranosyl)thymine (3a): A mixture of
thymine (838 mg, 6.7 mmol) in hexamethyldisilazane (120 mL),
chlorotrimethylsilane (0.85 mL), and dry pyridine (12 mL) was re-
fluxed overnight. After evaporation in vacuo, 2 (2.1 g, 5.5 mmol)
in dry 1,2-dichloroethane (50 mL) and trimethylsilyl trifluorome-
thanesulfonate (1.2 mL, 6.7 mmol) were added to the residue. After
5 h, CH2Cl2 (50 mL) and cooled 7% NaHCO3 solution (100 mL)
were added to the reaction mixture. The organic layer was sepa-
rated, washed twice with H2O (100 mL), dried with MgSO4, fil-
tered, and the solvents evaporated to dryness. The residue was dis-
solved in 0.15  NaOCH3 in CH3OH (100 mL), stirred for 1 h, and
neutralised with a H2O/CH3COOH (9:1) solution. The mixture was
evaporated in vacuo, purified by column chromatography (CH2Cl2/
MeOH, 95:5) and crystallised from CH3OH to yield 1.52 g (80%)
of the title compound 3a. 1H NMR (300 MHz, [D6]DMSO): δ 
1.77 [d, 4J  1.2 Hz, 3 H, C(5)-CH3], 3.54 [dd, 3J  3.2 Hz and
2J5a’,5b’  12.3 Hz, 1 H, C(5)-Hb], 3.63 [dd, 3J  3.0 Hz, 1 H,
C(5)-Ha], 3.84 [q, 3J  3.3 Hz and 3J  7.8 Hz, 1 H, C(4)-H],
4.06 [app t, 3J  5.1 Hz, 1 H, C(3)-H], 4.40 [t, 3J  5.7 Hz, 1 H,
C(2)-H], 5.29 [br. s, 1 H, C(5)-OH], 5.74 [d, 3J  5.7 Hz, 1 H,
C(1)-H], 6.13 [br. s, 1 H, C(2)-OH], 7.69 [d, 4j  1.2 Hz, 1 H,
C(6)-H], 11.35 [br. s, 1 H, N(3)-H] ppm. 13C NMR (75 MHz,
[D6]DMSO): δ  12.85, 61.50, 61.81, 74.37, 82.44, 88.27, 110.16,
136.77, 151.41, 164.34 ppm. Exact mass (ESI-MS, iPrOH:H2O)
calculated for C10H13N5O5Na [M  Na] 306.0814; found
306.0798.
O-2,2-Anhydro-1-(3-azido-3-deoxy-5-O-trityl-β-D-arabinofuran-
osyl)hymine (4): (1.43 g, 5.1 mmol) of 3a and trityl chloride (1.55 g,
5.6 mmol) were dissolved in dry pyridine (15 mL). The reaction
mixture was heated at 65 °C for 7 hours, stirred overnight at room
temperature and the solvents evaporated to dryness. The residue
was dissolved in CH2Cl2 (150 mL) and washed subsequently with
7 % NaHCO3 solution (150 mL) and water (150 mL). The organic
layer was dried with MgSO4, filtered, and the solvents evaporated
to dryness. The residue was chromatographed on a silica gel col-
umn prepared in CH2Cl2/MeOH (99:1) and eluted with CH2Cl2/
MeOH (97:3) to give 2.46 g (92.7 %) of 1-(3-azido-3-deoxy-5-O-
trityl-β--ribofuranosyl)thymine: 1H NMR (300 MHz,
[D6]DMSO): δ  1.42 [d, 4J  0.9 Hz, 3 H, C(5)-CH3], 3.19 [dd,
3J  2.9 Hz and 2J5a’,5b’  11.0 Hz, 1 H, C(5)-Hb], 3.29 [dd,
3J  3.8 Hz, 1 H, C(5)-Ha], 3.97 [m, 1 H, C(4)-H], 4.30 [q, 3J 
5.4 Hz and 3J  10.8 Hz, 1 H, C(3)-H], 4.57 [q, 3J  5.0 Hz and
3J  10.1 Hz, 1 H, C(2)-H], 5.76 [d, 3J  5.4 Hz, 1 H, C(1)-H],
6.24 [d, 3J  4.8 Hz, 1 H, C(2)-OH], 7.217.40 [m, 15 H, trityl],
7.46 [d, 4J  1.2 Hz, 1 H, C(6)-H], 11.40 [s, 1 H, N(3)-H] ppm.
Exact mass (ESI-MS, iPrOH/H2O) calculated for C29H27N5O5Na
[M  Na] 548.1910; found 548.1910. Trifluoromethanesulfonyl
chloride (1.0 mL, 9.36 mmol) was added to a cooled solution of 1-
(3-azido-3-deoxy-5-O-trityl-β--ribofuranosyl)thymine (2.46 g,
4.68 mmol) and DMAP (2.30 g, 18.7 mmol) in dry CH2Cl2
(50 mL). After 2 hours the reaction was quenched with water
(15 mL) and extracted. The organic layer was washed with a 7 %
NaHCO3 solution, dried with MgSO4, filtered, and the solvents
evaporated to dryness to give a white semi-solid that was purified
on a silica gel column (CH2Cl2/MeOH, 97/3) to give 1.91 g (81 %)
of 4. 1H NMR (300 MHz, [D6]DMSO): δ  1.79 [d, 4J  0.9 Hz,
3 H, C(5)-CH3], 2.77 [dd, 3J  7.6 Hz and 2J5a’,5b’  10.6 Hz, 1
H, C(5)-Hb], 3.04 [dd, 3J  4.1 Hz, 1 H, C(5)-Ha], 4.38 [m, 1 H,
C(4)-H], 4.60 [dd, 3J  1.8 Hz and 3J  3.2 Hz, 1 H, C(3)-H],
5.43 [dd, 3J  1.6 Hz and 3J  5.7 Hz, 1 H, C(2)-H], 6.31 [d, 3J 
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5.7 Hz, 1 H, C(1)-H], 7.207.28 [m, 15 H, trityl], 7.82 [d, 4J 
1.2 Hz, 1 H, C(6)-H] ppm. Exact mass (ESI-MS, iPrOH:H2O) cal-
culated for C29H26N5O4 [M  H] 508.1984; found 508.1982.
1-(3-Azido-3-deoxy-5-O-trityl-β-D-arabinofuranosyl)thymine (5): A
mixture of 4 (1.91 g, 3.76 mmol), 1  NaOH (10 mL), and 50 %
EtOH (100 mL) was stirred at room temperature for 4 hours. The
solution was neutralised with HOAc:EtOH (1:1, v/v) to pH  7.
The resulting white solid was collected by filtration and washed
with water. The solid was then dissolved in CH2Cl2, extracted with
water, dried with MgSO4, filtered, and evaporated to dryness to
produce 1.74 g (88.1 %) of 5 as a white solid. 1H NMR (300 MHz,
[D6]DMSO): δ  1.59 [d, 4J  0.6 Hz, 3 H, C(5)-CH3], 3.28 [dd,
3J  4.1 Hz and 2J5a’,5b’  11.1 Hz, 2 H, C(5)-Ha,b], 3.80 [app
quinted, 3J  4.1 Hz and 3J  8.2 Hz, 1 H, C(4)-H], 4.15 [t, 3J 
7.5 Hz, 1 H, C(3)-H], 4.34 [m, 1 H, C(2)-H], 6.07 [d, 3J  6.2 Hz,
1 H, C(1)-H], 6.10 [d, 3J  5.6 Hz, 1 H, C(2)-OH], 7.247.40 [m,
15 H, trityl], 7.38 [d, 4J  0.6 Hz, 1 H, C(6)-H], 11.34 [s, 1 H, N(3)-
H] ppm. Exact mass (ESI-MS, iPrOH:H2O) calculated for
C29H27N5O5Na [M  Na] 548.1910; found 548.1906.
1-(3-Azido-3-deoxy-β-D-arabinofuranosyl)thymine (6a): A suspen-
sion of compound 5 (0.5 g, 0.95 mmol) in 80% HOAc (10 mL) was
heated at 90 °C with stirring for 25 min. The solution was evapo-
rated in vacuo to give a residue that was chromatographed on a
silica gel column (CH2Cl2/MeOH, 95:5) to afford 0.2 g (78.6 %) of
6a. 1H NMR (300 MHz, [D6]DMSO): δ  1.74 [s, 4J  1.2 Hz, 3
H, C(5)-CH3], 3.62 [m, 3 H, C(4)-H and C(5)-Ha,b], 4.00 [t, 3J 
7.5 Hz, 1 H, C(3)-H], 4.32 [t, 3J  6.6 Hz, 1 H, C(2)-H], 5.29 [br.
s, 1 H, C(5)-OH], 5.99 [d, 3J  6.2 Hz, 1 H, C(1)-H], 6.07 [d,
3J  0.6 Hz, 1 H, C(2)-OH], 7.58 [d, 4J  1.2 Hz, 1 H, C(6)-H],
11.27 [s, 1 H, N(3)-H] ppm. 13C NMR (75 MHz, [D6]DMSO): δ 
12.84, 60.20, 64.84, 74.80, 80.26, 83.78, 108.70, 138.29, 151.14,
164.503 ppm. Exact mass (ESI-MS, iPrOH:H2O) calculated for
C10H13N5O5Na [M  Na] 306.0814; found 306.0810.
1-(3-Azido-2-chloro-2,3-dideoxy-β-D-ribofuranosyl)thymine (7a):
(310 mg, 0.61 mmol) of 4 was transferred into a sealable glass vial
and 4  HCl in dioxane (20 mL) was added. The vial was firmly
sealed and temperature was raised to 7580 °C for 24 hours. After
cooling to room temperature the reaction mixture was evaporated
in vacuo and purified on a silica gel column CH2Cl2/MeOH (98:2)
to give 170 mg (92 %) of 7a. 1H NMR (300 MHz, [D6]DMSO):
δ  1.75 [d, 4J  1.2 Hz, 3 H, C(5)-CH3], 3.61 [ddd, 3J  3.0 Hz
and 3J  5.0 Hz and 2J5a’,5b’  12.6 Hz, 1 H, C(5)-Hb], 3.75
[ddd, 3J  3.1 Hz and 3J  5.3 Hz, 1 H, C(5)-Ha], 3.99 [app
quinted, 3J  2.9 Hz and 3J  3.13 Hz and 3J  6.0 Hz, 1 H,
C(4)-H], 4.57 [t, 3J  5.7 Hz, 1 H, C(3)-H], 4.92 [t, 3J  5.1 Hz,
1 H, C(2)-H], 5.47 [t, 3J  4.7 Hz, 1 H, C(5)-OH], 5.93 [d, 3J 
4.7 Hz, 1 H, C(1)-H], 7.80 [d, 4J  1.2 Hz, 1 H, C(6)-H], 11.46 [s,
1 H, N(3)-H] ppm. 13C NMR (75 MHz, [D6]DMSO): δ  12.92,
60.37, 61.10, 61.90, 83.12, 89.02, 110.23, 135.89, 151.17,
164.29 ppm. Exact mass (ESI-MS, iPrOH:H2O) calculated for
C10H13Cl1N5O4 [M  H] 302.0655; found 302.0658.
1-(3-Azido-2,3-dideoxy-2-fluoro-β-D-ribofuranosyl)thymine (8a): To
a solution of 5 (1.59 g, 3.0 mmol) in toluene (30 mL) and pyridine
(3 mL), DAST (1.5 mL, 11.3 mmol) was added and stirred at room
temperature for 2 h before heating the reaction mixture to 50 °C.
After 5 hours EtOAc (170 mL) was added and the organic layer
washed successively with 7 % NaHCO3 (200 mL) and H2O
(200 mL), dried with MgSO4, filtered, and concentrated in vacuo.
The residue was purified on a silica gel column prepared in CHCl3
and eluted with CHCl3/MeOH, 99:1 to give 1.45 g (90 %) of 1-(3-
azido-2,3-dideoxy-2-fluoro-5-O-trityl-β--ribofuranosyl)thymine:
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1H NMR (300 MHz, [D6]DMSO): δ  1.52 [d, 4J  0.9 Hz, 3 H,
C(5)-CH3], 3.24 [dd, 3J  4.1 Hz and 2J5a’,5b’  11.1 Hz, 1 H,
C(5)-Hb], 3.35 [dd, 3J  2.4 Hz, 1 H, C(5)-5a], 4.12 [m, 1 H, C(4)-
H], 4.56 [ddd, 3J  4.7 Hz and 3J  9.5 Hz and 3J3,F  24.5 Hz,
1 H, C(3)-H], 5.53 [dd, 3J  4.8 Hz and 2J2,F  52.9 Hz, 1 H,
C(2)-H], 5.91 [dd, 3J  1.1 Hz and 3J1,F  21.6 Hz, 1 H, C(1)-
H], 7.247.40 [m, 15 H, trityl], 7.51 [d, 4J  1.2 Hz, 1 H, C(6)-H],
11.51 [br. s, 1 H, N(3)-H] ppm. Exact mass (ESI-MS, iPrOH:H2O)
calculated for C29H26F1N5O4Na [M  Na] 550.1866; found
550.1862. 1-(3-Azido-2,3-dideoxy-2-fluoro-5-O-trityl-β--ribofur-
anosyl)thymine (1.45 g, 2.75 mmol) was detritylated to 0.52 g (64
%) of 8a (see procedure 6a). 1H NMR (300 MHz, [D6]DMSO): δ 
1.74 [d, 4J  1.2 Hz, 3 H, C(5)-CH3], 3.60 [dd, 3J  2.9 Hz and
2J5a’,5b’  12.6 Hz, 1 H, C(5)-Hb], 3.79 [dd, 3J  2.6 Hz, 1 H,
C(5)-Ha], 3.98 [dt, 3J  2.6 Hz and 3J  8.8 Hz, 1 H, C(4)-H],
4.30 [ddd, 3J  4.6 Hz and 3J  8.9 Hz and 3J3,F  23.5 Hz, 1 H,
C(3)-H], 5.42 [ddd, 3J  1.5 Hz and 3J  4.5 Hz and 2J2,F 
52.9 Hz, 1 H, C(2)-H], 5.43 [br. s, 1 H, C(5)-OH], 5.90 [dd, 3J 
1.6 Hz and J1,F  19.2 Hz, 1 H, C(1)-H], 7.74 [d, 4J  1.2 Hz, 1
H, C(6)-H], 11.44 [br. s, 1 H, N(3)-H] ppm. 13C NMR (75 MHz,
[D6]DMSO): δ  12.76, 58.67 (J  15.3 Hz), 59.76, 81.65, 88.38
(J  34.8 Hz), 94.68 (J  186.3 Hz), 110.10, 136.89, 150.84,
164.51 ppm. Exact mass (ESI-MS, iPrOH:H2O) calculated for
C10H12F1N5O4Na [M  Na] 308.0771; found 308.0759.
General Procedure for the Synthesis of the 3-Amine-Modified Nu-
cleosides 3b, 6b8b from the 3-Azide-Modified Nucleosides 3a, 6a-
8a: The 3-azido-modified nucleoside (1 mmol) was dissolved in dry
pyridine (8 mL) and PhP3 (1.6 mmol) was added to the solution.
After stirring at room temperature for 1.5 h, concentrated NH4OH
(3 mL) was added. The reaction mixture was stirred for another
2 h, evaporated to dryness and purified by silica gel chromatogra-
phy (CH2Cl2/MeOH).
1-(3-Amino-3-deoxy-β-D-ribofuranosyl)thymine (3b): (500 mg,
1.77 mmol) of 3a yielded 320 mg (71 %) of 3b as a white solid. 1H
NMR (300 MHz, [D6]DMSO): δ  1.75 [s, 3 H, C(5)-CH3], 3.21
[dd, 3J  5.4 Hz and 3J  7.7 Hz, 1 H, C(3)-H], 3.60 [m, 2 H,
C(4)-H and C(5)-Hb], 3.74 [app d, 2J5a’,5b’  11.2 Hz, 1 H,
C(5)-Ha], 3.86 [dd, 3J  2.4 Hz and 3J  5.3 Hz, 1 H, C(2)-H],
5.11 [br. s, 1 H, C(5)-OH], 5.69 [d, 3J  2.4 Hz, 1 H, C(1)-H],
7.61 [s, 1 H, C(6)-H] ppm. 13C NMR (75 MHz, [D6]DMSO): δ 
12.85, 52.42, 60.74, 75.39, 85.55, 90.12, 109.29, 137.16, 151.13,
164.48 ppm. Exact mass (ESI-MS, iPrOH:H2O) calculated for
C10H16N3O5Na [M  H] 258.1089; found 258.1095.
1-(3-Amino-3-deoxy-β-D-arabinofuranosyl)thymine (6b): (120 mg,
0.42 mmol) of 6a yielded 60 mg (54%) of 6b as a white solid. 1H
NMR (300 MHz, [D6]DMSO): δ  1.73 [d, 4J  1.2 Hz, 3 H, C(5)-
CH3), 3.05 [t, 3J  6.2 Hz, 1 H, C(3)-H], 3.50 [m, 1 H, C(4)-H],
3.61 [app t, 2J5a’,5b’  15.8 Hz, 2 H, C(5)-Ha,b], 3.90 [br. q, 3J 
5.0 Hz and 3J  9.7 Hz, 1 H, C(2)-H], 5.04 [s, 1 H, C(5)-OH],
5.42 [d, 3J  4.4 Hz, 1 H, C(2)-OH], 5.98 [d, 3J  5.6 Hz, 1 H,
C(1)-H], 7.60 [d, 4J  1.2 Hz, 1 H, C(6)-H] ppm. 13C NMR
(75 MHz, [D6]DMSO): δ  12.88, 57.83, 60.99, 77.41, 84.54, 84.66,
107.97, 138.82, 151.15, 164.59 ppm. Exact mass (ESI-MS, iP-
rOH:H2O) calculated for C10H16N3O5 [M  H] 258.1089; found
258.1084.
1-(3-Amino-2-chloro-2,3-dideoxy-β-D-ribofuranosyl)thymine (7b):
(90 mg, 0.30 mmol) of 7a yielded 24 mg (30 %) of 7b as a white
solid. 1H NMR (300 MHz, [D6]DMSO): δ  1.73 [d, 4J  0.9 Hz,
3 H, C(5)-CH3], 1.85 [br. s, 2 H, C(3)-NH2], 3.50 [dd, 3J  5.3 Hz
and 3J  7.9 Hz, 1 H, C(3)-H], 3.62 [ddd, 3J  2.6 Hz and 3J 
4.7 Hz and 2J5a’,5b’ 12.2 Hz, 1 H, C(5)-Hb], 3.75 [m, 2 H, C(4)
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and C(5)-Ha], 4.53 [dd, 3J  2.4 Hz and 3J  5.3 Hz, 1 H, C(2)-
H], 5.26 [t, 3J  5.0 Hz, 1 H, C(5)-OH], 5.94 [d, 3J  2.6 Hz, 1
H, c(1)-H], 7.99 [d, 4J  1.5 Hz, 1 H, C(6)-H], 11.35 [s, 1 H, n(3)-
H] ppm. 13C NMR (75 MHz, [D6]DMSO): δ  12.91, 52.06, 59.97,
84.69, 89.64, 91.10, 109.64, 136.22, 151.09, 164.42 ppm. Exact mass
(ESI-MS, iPrOH:H2O) calculated for C10H15Cl1N3O4 [M  H]
276.0750; found 276.0765.
1-(3-Amino-2,3-dideoxy-2-fluoro-β-D-ribofuranosyl)thymine (8b):
120 mg, 0.42 mmol of 8a yielded 60 mg (55 %) of 8b as a white
solid. 1H NMR (300 MHz, [D6]DMSO): δ  1.72 [d, 4J  1.2 Hz,
3 H, C(5)-CH3], 3.32 [ddd, 3J  4.3 Hz and 3J  9.7 Hz and
3J3,F  28.6 Hz, 1 H, C(3)-H], 3.61 [m, 2 H, C(4)-H and C(5)-
Hb], 3.78 [dd, 3J  1.76 Hz and 2J5a’,5b’  12.3 Hz, 1 H, C(5)-
Ha], 4.87 [dd, 3J  4.1 Hz and 2J2,F  53.1 Hz, 1 H, C(2)-H], 5.19
[br. s, 1 H, C(5)-OH], 5.83 [d, 3J1,F  18.2 Hz, 1 H, C(1)-H], 7.86
[d, 4J  1.2 Hz, 1 H, C(6)-H] ppm. 13C NMR (75 MHz,
[D6]DMSO): δ  12.82, 51.73 (J  18.1 Hz), 59.54, 84.83, 88.30
(J  35.7 Hz), 96.72 (J  180.5 Hz), 109.54, 136.80, 150.79,
164.52 ppm. Exact mass (ESI-MS, iPrOH:H2O) calculated for
C10H15F1N3O4 [M  H] 260.1046; found 260.1053.
TMPK Assay: Activity was determined by using the coupled spec-
trophotometric assay at 334 nm (0.5 mL final volume) in an Eppen-
dorf ECOM 6122 photometer.[31] One unit of enzyme activity
corresponds to 1 µmol of the product formed in 1 minute at 30 °C
and pH 7.4. The concentration of ATP and dTMP were kept con-
stant at 0.5 m and 0.05 m, respectively, whereas the concen-
trations of analogues varied between 0.01 m and 4 m. The reac-
tion medium (0.5 mL final volume) contained 50 m of
tris(hydroxymethyl)aminomethane·HCl (pH 7.4), 50 m of KCl,
2 m of MgCl2, 0.2 m of NADH, 1 m ofphosphoenol pyruvate,
and 2 units each of lactate dehydrogenase, pyruvate kinase, and
nucleoside diphosphate kinase.
Pseudorotational Analysis: NMR samples were prepared with 3 mg
of compounds 7ab and 8ab, dissolved in 250 µL of D2O and the
pD was adjusted to 7.4 (same conditions used during the TMPKmt
assay). High resolution 1D 1H spectra were recorded on a Varian
500 MHz Unity spectrometer, operating at 499.505 MHz. Quadra-
ture detection was achieved by States-Haberkorn hypercomplex
mode.[32] Coupling constants were examined for all four analogues
between 278 K and 333 K. The ring conformations of the synthetic
nucleosides were analysed with the program PSEUROT 6.2[26]
(DOS version) running on a Pentium II 350-MHz personal com-
puter. This version includes an improved generalized Karplus equa-
tion for the iterative generation of coupling constants based on the
experimental data as described by Donders et al.[33] The standard
values for substituent electronegativities (supplied with the 6.2 ver-
sion)[26] were used in the iterations. For the azide function the λ-
value of 0.85 was used.[22b] For the calculations an iterative strategy
was adopted in which the pseudorotational parameters, obtained
for each set of coupling constants, were calculated repeatedly after
minor changes were systematically made in the starting parameters.
If there was reason to believe that a specific derivative preferred a
particular ring puckering, the minor conformer was held fixed dur-
ing the iteration. The quality of the data was measured in the RMS
deviation of the calculated and experimental coupling constants. In
general, the RMS deviation (between the experimental and calcu-
lated coupling constants) was less than 0.2, indicating the param-
eterisation of the program was well suited to the input data (see
Table 3).
NoS Energy Calculations: For each compound, the mole fraction
of S (Xs) at each temperature interval (see Table 2.), obtained from
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the PSEUROT[26] analysis, was used to make the van’t Hoff plots
(not shown here). The slopes and intercepts of these van’t Hoff
plots were subsequently used to calculate the ∆H° and ∆S° of the
NoS two-state pseudorotational equilibrium of compounds 7ab
and 8ab (see Table 4). The correlation coefficients (R2) of the
van’t Hoff plots are: 0.96 (7a), 0.93 (7b), 0.81 (8a), and 0.92 (8b).
∆G° and XS were calculated at 303 K by using the determined ∆H°
and ∆S° values (see Table 4).
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